AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01522391
Drug: DPK-060 1% ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
Trial: NCT01522391
Drug: Placebo for DPK-060 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
Trial: NCT02840552
Drug: 18F-Fluoromethylcholine (18F-FCH)
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCH PET/CT
Trial: NCT00554229
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD4054 10 mg oral tablet once daily
Trial: NCT00554229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral tablet once daily
Trial: NCT00214942
Drug: ORAVESCENT Fentanyl Citrate
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02389868
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01353313
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Trial: NCT01353313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Trial: NCT02490111
Drug: DWJ1319
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02490111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05164003
Drug: CORETOX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
Trial: NCT05164003
Drug: BOTOX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
Trial: NCT00795717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules given twice daily
Trial: NCT01742013
Drug: GCJBP Laennec Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT01742013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT00954356
Drug: XPF-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
Trial: NCT00954356
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of 5 x 100 mg Placebo capsules.
Trial: NCT04571944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant-matching placebo administered QD via oral tablet
Trial: NCT00270881
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 120mg/kg
Trial: NCT00939549
Drug: Cyclophosphamide/Glatiramer acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
Trial: NCT04665453
Drug: Melatonin 0,1mg/kg oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonine in the form of syrup will be given orally to child.
Trial: NCT02545504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously on Days 1 and 15 of each treatment cycle
Trial: NCT02545504
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Trial: NCT02209155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00812994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04609943
Drug: BAY1211163
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
Trial: NCT04278599
Drug: Oral Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the test group, the patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. They will also be will be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
Trial: NCT04278599
Drug: Oral placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control group, the patients will be administered Placebo tablets for 6 weeks from the baseline. They will also be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
Trial: NCT00689039
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER tablet, administered as single and repeated doses.
Trial: NCT00689039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, administered as single and repeated doses.
Trial: NCT04426734
Drug: Topical Prednisolone Acetate 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30
Trial: NCT00629980
Drug: AzaSite®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Trial: NCT04076865
Drug: EMLA (lidocaine) +Itch (Histamine and cowhage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain.
Trial: NCT01632527
Drug: HuCNS-SC cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
Trial: NCT00619034
Drug: Latanoprost, diclofenac and dorzolamide (eyedrops)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 eyedrop twice daily in one week
Trial: NCT00619034
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dicolfenac eyedrops twice daily i one eye
Trial: NCT02997215
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion at same rate as intervention group during surgery
Trial: NCT02155660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive
Trial: NCT02257398
Drug: GSK2140944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
Trial: NCT02257398
Drug: GSK2140944 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
Trial: NCT04827069
Drug: Clifutinib Besylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Trial: NCT00216346
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04184050
Drug: MK-4002
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04651153
Drug: UCB7853
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive UCB7853 at pre-specified time-points.
Trial: NCT01189396
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo DPI with 0 mcg Albuterol/inhalation
Trial: NCT03812224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection once a month
Trial: NCT01101321
Drug: Reformulated OXY (Totowa) (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
Trial: NCT01101321
Drug: Reformulated OXY (Wilson) (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
Trial: NCT02678182
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2/day, 21 day cycle
Trial: NCT02678182
Drug: MEDI4736 (Durvalumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV treatment on days 1\&15 of 28 day cycle
Trial: NCT00104299
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg/kg/day orally for months 4-6
Trial: NCT03215056
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03371498
Drug: Methylprednisolone placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
Trial: NCT00575003
Drug: CYT003-QbG10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subcutaneous injections
Trial: NCT00431132
Drug: estradiol, 10 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, administered intravaginally twice weekly
Trial: NCT01447758
Drug: LEO 29102
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
Trial: NCT01447758
Drug: LEO 29102 Cream Vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
Trial: NCT03826641
Drug: HCP1805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
Trial: NCT01071902
Drug: Moxidex otic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Trial: NCT02085460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02197884
Drug: JNJ-54861911, 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
Trial: NCT02197884
Drug: Clarithromycin 500 mg
RxNorm normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
Trial: NCT01440231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered by subcutaneous injection, once weekly
Trial: NCT03976882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01673204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619176
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate: 7.5mg/week to 15mg/week for 3 months
Trial: NCT01619176
Drug: non-steroidal anti-inflammatory drug (NSAID)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID: 100mg twice a day for 3 months
Trial: NCT03178149
Drug: ASP7317
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subretinal injection
Trial: NCT04330326
Drug: Metabolic Cofactor Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
Trial: NCT04330326
Drug: Sorbitol
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
Trial: NCT03907852
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: lymphodepletion chemotherapy
Trial: NCT01048593
Drug: IBI-10090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraocular injection
Trial: NCT03265964
Drug: Uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uridine is the active treatment in this clinical trial.
Trial: NCT03265964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Trial: NCT01258738
Drug: Background NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
Trial: NCT01258738
Drug: Background NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
Trial: NCT01211795
Drug: topical intraoral ketoprofen gel
RxNorm normalized name: ketoprofen Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
Trial: NCT02418000
Drug: E6201
RxNorm normalized name: TRACH STOMA PROTECTOR,CLOTH WHITE BE6201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Group Assignment
Trial: NCT00080158
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00087152
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
Trial: NCT00689611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03172026
Drug: Placebo 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
Trial: NCT00508001
Drug: Best Supportive Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Best Supportive Care
Trial: NCT04419558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution for injection
Trial: NCT02205580
Drug: continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02205580
Drug: continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02205580
Drug: continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01486979
Drug: estradiol, 25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
Trial: NCT01787123
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of intravenous normal saline started within 4 days of ictus
Trial: NCT01226134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules,thrice a day for four weeks
Trial: NCT04298320
Drug: AIN 457
RxNorm normalized name: Ainsliaea fragrans top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 was administered 150mg or 300mg ih every 2 weeks
Trial: NCT01735422
Drug: r-hLH
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
Trial: NCT01735422
Drug: u-hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
Trial: NCT00787527
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
Trial: NCT00787527
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
Trial: NCT02485873
Drug: Vitamin K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by treating physicians
Trial: NCT04151212
Drug: BAT5906 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
Trial: NCT02973386
Drug: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
Trial: NCT01561014
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02807051
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
Trial: NCT02807051
Drug: Pacritinib and Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
Trial: NCT00000125
Drug: Topical ocular hypotensive eye drops.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular hypotensive eye drops.
Trial: NCT04100083
Drug: Spironolactone 50 MG
RxNorm normalized name: spironolactone 50 MG
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.